Start With EYLEA. Stay With EYLEA.1
TRUST 8 YEARS OF EXTENSIVE CLINICAL EXPERIENCE AND THE INTEGRITY OF DATA FROM LARGE, WELL–CONTROLLED CLINICAL TRIALS1
EYLEA is the #1 prescribed anti–VEGF FDA approved for Wet AMD, DME, and MEfRVO*
*IBM Truven MarketScan data: Number of injections administered from Q4 2017 through Q3 2018; data on file.
The Established Experience of EYLEA1,2

8 years of real–world experience1

An estimated 9 million doses administered to ≈790,000 eyes since launch (and counting)2

8 phase 3 clinical trials including more than 3000 EYLEA–treated patients across all approved indications: Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (MEfRVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR)1
EYLEA 2 mg (0.05 mL) Dosing Schedule1
MEfRVO | Dosing |
2 mg every 4 weeks |


ONLY EYLEA IS APPROVED TO TREAT 4 RETINAL CONDITIONS
WITH ONE SINGLE-DOSE-STRENGTH PRE-FILLED SYRINGE (PFS)1
IN STOCK AND AVAILABLE FOR ORDERING

The PFS offers a more convenient way to prepare EYLEA for administration when compared to vials:1
- Fewer components to handle
- Helps eliminate multiple preparation steps

One dosage strength may help:
- Simplify ordering and billing
- Streamline inventory management
Preparation of the single-dose, pre-filled syringe for intravitreal administration

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

Find complete product support—
guiding you through
orders, returns, and more.